BIOCON LIMITED Delivering Affordable Innovation

Group 6 Arjun Sreenivasan123 Raju Patowary- 166 Maru Gaurav- 142

Indias Foremost Biotech Company

3/7/13

11

Overview of Biotechnological Sector

Indian Bio Technology sector is among the five rising biotech industries in the region of Asia-Pacific.

The Indian Bio Tech industry is the biggest producer of vaccine in the world.

3/7/13

There are 325 different companies with the Indian

22

GDP- Composition by sector

3/7/13

33

INDIAN BIOTECHNOLOGICAL SECTOR-SEGMENT

The Bio Tech industry in India has the maximum number of companies operating under it.

The growth rate of the sector is around 35 to 40 % annually.

3/7/13

44

Backgrou nd

Biocon was found in November 29th 1978 Focused from enzymes manufacturing to development of Biopharmaceuticals Indias first billion dollar biotech company

1st in India and 20th in world in terms of revenue and market capitalization
Joint 3/7/13 venture between Leslie Auchincloss and Kiran Mazumdar 55

Mileston es

3/7/13

1978: Biocon India collaborated with Biocon Chemicals Ltd. 1979: Manufactured and exported enzymes to USA and Europe 1989: Unilever acquired Biocon Chemicals Ltd. 1994: Establishes Syngene 1996: Entered Pharmaceuticals and Statins 1998: Biocon buys Unilevers shareholding and became an independent entity 2000: Establishes Clingene 2001: US FDA approval for manufacture of Lovastatin 2003: First company to develop human insulin on a Pichia expression system 2006: Launches Indias first 66 anticancer

BIOCON AND ITS SUBSIDIARIES

3/7/13

77

NE WS

NE WS

3/7/13

88

3/7/13

99

CEO- Mrs. Kiran Mazumdar -Shaw

1953- Born in India

1973- B.sc in Zoology

3/7/13

1975- Master in Melting & brewing from Ballarat College , Melbourne 1010 University

3/7/13

1111

Contribution of each of the components of Biocons income expressed as a percentage of Biocons total

3/7/13

1212

THE DEALS THAT ARE CHANGING THE GAME

3/7/13 1313

Products

3/7/13

1414

3/7/13

INSUGEN 30/70 40 IU INSUGEN 50/50 40 IU INSUGEN N 40 IU INSUGEN R 40 IU Active Ingredient: Each ml contains Human Insulin (rDNA origin). Indication: In Diabetes, useful when EZ STATIX - oral agents Ingredient: Active fail to control blood glucose levels Atorvastatin 10 mg tablets. Indication: Controls extremely 1515 high levels of cholesterol

3/7/13

FINANCE

1616

Overview of Financial Strengths

Biocon Limited serves partners and customers in over 50 countries

It ranks first in Asias Biotech Industry in terms of Market Capitalization.

v

Biocon Limited had its Initial Public Offering (IPO) in 2004

v

3/7/13

Second Indian company to cross a market capitalization of 1 Billion US dollars on the first day of listing.
v

1717

Biocons Finances stem from major areas:-

Biopharmaceutical Products- such as branded and generic drugs, APIs

v

Customer Research Services- in the areas of preclinical and clinical research

v v

Manufacturing and Marketing

3/7/13

1818

FINANCIAL YEAR ENDING MARCH

Click to edit Master subtitle style

Please click here to see Profit and Lo

3/7/13

Sales, Expenditure and Profit from FY2007 to FY2011

Figure in Rs. (Crores)

10 9 8 7 6 5 4 3 2 1 0 3/7/13

Click to edit Master subtitle style

52 Week High, Low Share Price

Last Five Years High, Low Share Price

3/7/13

2121

Competitors

Wednesday, 3/7/13

2222

Competitors List

3/7/13

2323

Sun Pharmaceuticals Industries Ltd. (Oncology) o Now at a stage of rapid growth across geographies spanning Russia, China, South East Asia, Africa and Latin America.

3/7/13

No. 1 in India in speciality therapy areas like psychiatry, Wockhardt Limited neurology, cardiology among the top 3 companies in a o A recent addition to the companys total of 7 therapy areas. product basket is Wosulin Pen and Catridge, an automatic insulin delivery
o

2424

SWOT Analysis
Strengt hs Weakne sses

Low Price Insugen price of $2.5 per 10ml Debt free and cash rich status Rich and expanding new drug 3/7/13 pipeline

Statin dependent Limited clientele -Revenue profile is highly concentrated.

2525

Opportu nities Market potential --Statins market likely to grow at a rate of 18% in the next year India has the most quantity and diverse type of 3/7/13 diabetes.

Threats

Regulatory risk Competitive threat

Raw materials and fuel costs are linked to global commodity prices.

2626 Dollar depreciation----

Corporate Social It started a corporate social responsibility wing the Biocon Foundation Responsibility in 2004 through which it works in the areas of health, education and
infrastructure, especially in rural areas.

Health Through the Arogya Raksha Yogana (ARY) clinics, Biocon helps meet the primary, tertiary and secondary healthcare needs of various communities. Education In a scheme aimed at popularising mathematics among Karnatakas rural children, Biocon has started the Chinnara Ganitha program.

Infrastructure The Biocon Foundation has helped build infrastructure in several communities by constructing school buildings, crches, sanitary facilities, and water supply connections.

Flood Relief When floods devastated North Karnataka in September/October 2009, the Biocon Foundation dispatched doctors and nurses and helped treat more than 5,000 patients. The Foundation is also helping rebuild 1,000 homes destroyed in the floods in three affected villages of Bagalkot district. 3/7/13 2727

India 2000- Technology Pioneer Recognition, World Economic Forum 2004-India's first and No. 1 biotech company with a global ranking of 16* (Source: Biospectrum July 2004) 2006-Best IT User Award in the Pharmaceutical Sector, NASSCOM 2009-Biocon among Top 20 Indian companies in Forbes Best Under A Billion list. 2009-Biocon bags IDMA "Best Patent of the year" award 2009-Biocon wins prestigious BioSingapore Asia Pacific Biotechnology Award for Best Listed Company. 2010-Biocon wins Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector at Bangalore Bio
3/7/13 2828

Awards and Achievements 1985- National Award for Best Small Industry, Government of

3/7/13

2929